Yle

YLE Therapeutics is a preclinical-stage biotechnology company dedicated to developing first-in-class small molecule therapies for neurodegenerative diseases. The company's research focuses on proteinopathy, specifically targeting the misfolding and aggregation of the TDP-43 protein, which is a key pathological driver in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). By utilizing a proprietary drug discovery platform, YLE Therapeutics identifies compounds that can prevent or reverse toxic protein aggregation to preserve neuronal health. Headquartered in the San Francisco Bay Area, the company aims to address significant unmet medical needs in the field of neurodegeneration through its innovative approach to proteostasis.